Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its weight-loss drugs.

Could Viking's rapidly declining valuation be a sign that the bubble has burst for it, given its inflated price, or is the healthcare stock due for a big rally this year? Shares of Viking soared early last year after the company posted encouraging data for VK2735 from a phase 2 clinical trial,